Antibody drug conjugates comprising sting agonists, combinations and methods of use
OwnerRaghida A. BUKHALID, Naniye Cetinbas +3inventors
InventorsRaghida A. BUKHALID, Naniye Cetinbas, Marc I. Damelin, Timothy B. Lowinger, Dorin Toader
Life of this patent
Estimating the term…
Abstract
The present disclosure provides combinations comprising HER2-targeted STING agonist antibody-drug conjugates and HER2-targeted therapies or immunotherapies. The present disclosure also provides uses of the combinations in treatment, e.g., treatment of cancer.
Claims30
A combination therapy comprising at least one HER2-targeted STING agonist antibody-drug conjugate and at least one HER2-targeted therapy or at least one immunotherapy, wherein the HER2-targeted STING agonist antibody-drug conjugate is a conjugate of Formula (A):
- wherein the conjugate comprises a HER2 antibody comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO:
- 5);
- a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO:
- 6);
- a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO:
- 7);
- and a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO:
- 12);
- a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO:
- 13);
- and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO:
- 14), and d15 is about 8.
Dependencies are inferred from the claim text.